Sunday, September 6, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 26, 2026

Stocks drop in tech sell-off

View original at finance.yahoo.com
Stocks drop in tech sell-off Traders at the New York Stock Exchange - Michael M. Santiago/Getty Images Global stocks plunged on Friday in a tech rout after Apple said it would increase prices by up to £300 because of AI costs…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Technology giants have ploughed hundreds of billions into building AI infrastructure, sending demand for chips soaring

    60% confidence

  • Apple's price increases showed the cost of AI had started to filter down into consumer demand

    60% confidence

  • OpenAI could delay its much-anticipated trillion-dollar float until next year (2027)

    60% confidence

  • Apple would increase prices by up to £300 because of AI costs

    60% confidence

  • The AI boom has led to a shortage of memory chips

    60% confidence

Data points we hold from this source

S&P 500 Index Fund · stock price7301.35 index_points
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
Stocks drop in tech sell-off — Source | Via News | Via News